
Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Rein Therapeutics and keeping the price target at $4.00. Jason McCarthy’s rating is based on several factors, including the
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| RNTX | Rein Therapeutics | 0.37 | -0.94 | -71.83% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.37 | -71.83% |

Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Rein Therapeutics and keeping the price target at $4.00. Jason McCarthy’s rating is based on several factors, including the

Rein Therapeutics ( ($RNTX) ) just unveiled an update. On November 16, 2026, Rein Therapeutics reported preliminary blinded 12-week observations from its ongoing Phase 2 RENEW trial of inhaled LTI-03

Rein Therapeutics (RNTX) announced preliminary blinded twelve-week observations from the ongoing RENEW Phase 2 trial evaluating its lead drug candidate, LTI-03, in patients with idiopathic pulmonary fibrosis. Preliminary blinded safety

Rein Therapeutics, Inc (RNTX) is scheduled to report 3rd quarter earnings on 11/06/2026. Regarding Q3 estimates, Wall Street analysts expect Rein Therapeutics, Inc to post earnings of -$0.10 per share.

Rein Therapeutics ( ($RNTX) ) has shared an update. On September 4, 2026, Rein Therapeutics published a detailed investor and scientific presentation on its website outlining progress for its LTI-03

The latest announcement is out from Rein Therapeutics ( ($RNTX) ). On August 21, 2026, Rein Therapeutics received a delisting notice from the Nasdaq Stock Market after its common stock’s

Rein Therapeutics (RNTX) announced that the FDA has granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis. Published first on TheFly – the ultimate source for

Maxim Group analyst Jason McCarthy maintained a Buy rating on Rein Therapeutics yesterday and set a price target of $4.00. Jason McCarthy has given his Buy rating due to a

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Rein Therapeutics and keeping the price target at $8.00. Brandon Folkes has given his Buy rating due to a

Rein Therapeutics ( ($RNTX) ) has shared an announcement. On July 20, 2026, Rein Therapeutics held its 2026 Annual Meeting of Stockholders, at which shareholders elected two Class III directors,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| May 20, 2027TBA | $30.65M | ― | ― | 0.01 | -0.20 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.